Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests), By Treatment (Medication, Antifungal Agents, Fluconazole, Itraconazole, Calcitriol, Corticosteroids, Others), By Dosage Form (Tablet, Capsule, Others), By Route of Administration (Oral, Others), By Age of Onset (Childhood, Adult, Adolescent), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Jan 2024

Code : CMI6538

Pages :172

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Autoimmune Polyglandular Syndrome Type 1 Market - Restraints

Lack of awareness: Autoimmune polyglandular syndrome type 1 is a rare autoimmune disease that affects multiple endocrine glands. However,a lack of overall awareness about this condition among patients as well as healthcare providers has been a major factor hindering the growth potential of this market. Due to the rare nature of the disease and presence of non-specific symptoms in the early stages, proper and timely diagnosis remains a challenge. This ultimately leads to the progression of the disease to more advanced forms over time. According to a study published in the Orphanet Journal of Rare Diseases in 2021, about 63% of patients with autoimmune polyglandular syndrome type 1 in Germany suffered a delay in diagnosis of more than 5 years. Such delayed diagnoses result in reduced treatment effectiveness and increase lifelong dependence on hormone replacement therapies. Initiatives to educate people and train healthcare providers can help address this and support optimized growth of this niche market.
High cost of treatment: The high cost of treatment is significantly hampering the growth of the autoimmune polyglandular syndrome type 1 market. Autoimmune polyglandular syndrome type 1 is a rare disorder that results from failure of immune system to recognize the body's own tissues. It requires lifelong treatment to manage the various conditions associated with it. However, the treatment process is very expensive, which many patients can't afford. The treatment depends on the symptoms presented in each patient but often involves hormone replacement therapy and immunosuppressive medications. Hormone replacement medicines like hydrocortisone, levothyroxine, etc. need to be taken throughout life, which costs thousands of dollars each year. Similarly, immunosuppressants have a high price tag. Both a lack of insurance schemes in low resource regions and high drug development costs pose major barriers to market expansion currently.

Global Autoimmune Polyglandular Syndrome Type 1 Market- Drivers

Increased incidence of autoimmune disorders: The increased incidence of autoimmune disorders has led to higher diagnosis rates of autoimmune polyglandular syndrome Type 1 (APS1) over the past decade. APS1 is a rare and complex genetic disorder that results from mutations in the Autoimmune Regulator Gene (AIRE) gene. It is characterized by the simultaneous or sequential destruction of two or more endocrine glands due to autoimmune attacks. Various research staudies show that the diagnosis rates of many autoimmune diseases, like type 1 diabetes, Addison's disease, hypothyroidism, etc., have risen significantly in the developed world. According to the Centers for Disease Control and Prevention (CDC) data from 2020, it is estimated that around 23.5 million Americans suffer from autoimmune diseases, which is nearly twice the number from 1999. As APS1 involves destruction of endocrine tissues, the rising incidence of underlying autoimmune conditions increases the risk of developing APS1. This has contributed to the growing demand for the diagnosis and treatment of APS1.